B
BlueWhale Bio
Empowering employees, fostering a culture of inclusivity and diversity, and inspiring innovation in cell and gene therapy with a career page for BlueWhale Bio
About BlueWhale Bio
BlueWhale Bio is a pioneering company in the biotechnology sector, focusing on the development and acceleration of cell-based therapies. The company serves a diverse range of clients, including research institutions, pharmaceutical companies, and healthcare providers. Operating in the rapidly growing cell therapy market, BlueWhale Bio leverages advanced data analytics and innovative scientific methods to create products that enhance the accessibility, speed, and affordability of cell therapies.
The business model of BlueWhale Bio revolves around the development and commercialization of high-quality cell therapy products. The company generates revenue through the sale of these products, as well as through partnerships and collaborations with other entities in the biotech and healthcare industries. By optimizing lab operations, maintaining stringent safety protocols, and fostering a culture of innovation, BlueWhale Bio ensures the delivery of superior products that meet the evolving needs of its clients.
Founded by renowned immunotherapy experts Carl June and James Riley, BlueWhale Bio is at the forefront of scientific discovery and technological advancement. The company is committed to refining and optimizing processes to enhance product quality and efficiency, thereby driving the growth and adoption of cell-based therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Philadelphia, United States
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 91.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2025 | $5M | $90M | Undisclosed | ↗ |
| SEED✓Equity / VC | Sep 2023 | $18M | $72M | Novalis Lifesciences · Danaher Ventures · Marshall Wace | ↗ |
Growth signals
Latest recorded traffic for BlueWhale Bio is 2.4K monthly website visits, up 14.3% over the last three months. BlueWhale Bio's team grew 1066.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- DVDanaher Ventures
Novalis Lifesciences
Marshall Wace
Other known investors1 additional known investor
University of Pennsylvania
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BlueWhale Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BlueWhale Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.